O’Connor JPB., Tessyman V., Little RA., Babur M., Forster D., Latif A., Cheung S., Lipowska-Bhalla G., Higgins GS., Asselin M-C., Parker GJM., Williams KJ.

Atovaquone (ATQ) induces modification of tumor hypoxia in Calu6 xenografts. A, TMR [18F] FAZA uptake is increased from baseline at day 7 in control tumors (Cn; white bars) but was reduced in drug-treated tumors. B, Example [18F] FAZA PET images, with greatest hypoxia represented by orange and red. C, Tumor MRI hypoxic fraction showed similar relative reduction at day 3 and 7, relative to control tumors. D, Example segmented MRI images showing hypoxic (blue), normoxic (yellow), and necrotic (gray) tumor. E, Lower percentage of pimonidazole staining was detected in drug-treated tumors at day 7, compared to controls. F, Example pimonidazole adduct formation images (×40 magnification).

Figure 3 from Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action

O’Connor JPB., Tessyman V., Little RA., Babur M., Forster D., Latif A., Cheung S., Lipowska-Bhalla G., Higgins GS., Asselin M-C., Parker GJM., Williams KJ.

DOI

Type

Publication Date